We’ve recently updated our valuation analysis.

GeoVax Labs Valuation

Is GOVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

4/6

Valuation Score 4/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GOVX?

Other financial metrics that can be useful for relative valuation.

GOVX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does GOVX's PB Ratio compare to its peers?

The above table shows the PB ratio for GOVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1x
OTLC Oncotelic Therapeutics
1xn/aUS$25.0m
EFTR eFFECTOR Therapeutics
1.6x-38.9%US$18.2m
ONVO Organovo Holdings
0.5xn/aUS$13.6m
RGLS Regulus Therapeutics
0.7x-1.7%US$28.5m
GOVX GeoVax Labs
0.7x34.2%US$21.0m

Price-To-Book vs Peers: GOVX is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1x).


Price to Earnings Ratio vs Industry

How does GOVX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Book vs Industry: GOVX is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.7x)


Price to Book Ratio vs Fair Ratio

What is GOVX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GOVX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GOVX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GOVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GOVX ($0.8) is trading below our estimate of fair value ($897.1)

Significantly Below Fair Value: GOVX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GOVX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.82
US$5.50
+570.7%
45.5%US$8.00US$3.00n/a2
Nov ’23US$0.91
US$7.00
+673.0%
14.3%US$8.00US$6.00n/a2
Oct ’23US$1.09
US$6.00
+450.5%
0%US$6.00US$6.00n/a1
Sep ’23US$1.14
US$6.00
+426.3%
0%US$6.00US$6.00n/a1
Aug ’23US$3.90
US$6.00
+53.8%
0%US$6.00US$6.00n/a1
Jul ’23US$0.81
US$6.00
+640.7%
0%US$6.00US$6.00n/a1
Jun ’23US$1.95
US$6.00
+207.7%
0%US$6.00US$6.00n/a1
May ’23US$0.79
US$6.00
+659.5%
0%US$6.00US$6.00n/a1
Apr ’23US$1.00
US$6.00
+500.0%
0%US$6.00US$6.00n/a1
Mar ’23US$1.75
US$6.00
+242.9%
0%US$6.00US$6.00n/a1
Feb ’23US$2.52
US$10.00
+296.8%
0%US$10.00US$10.00n/a1
Jan ’23US$3.62
US$10.00
+176.2%
0%US$10.00US$10.00n/a1
Dec ’22US$3.96
US$10.00
+152.5%
0%US$10.00US$10.00US$0.801
Nov ’22US$4.08
US$10.00
+145.1%
0%US$10.00US$10.00US$0.911
Oct ’22US$4.18
US$8.00
+91.4%
0%US$8.00US$8.00US$1.091
Sep ’22US$5.64
US$8.00
+41.8%
0%US$8.00US$8.00US$1.141
Aug ’22US$4.37
US$8.00
+83.1%
0%US$8.00US$8.00US$3.901
Jul ’22US$4.82
US$8.00
+66.0%
0%US$8.00US$8.00US$0.811
Jun ’22US$5.14
US$8.00
+55.6%
0%US$8.00US$8.00US$1.951
May ’22US$5.44
US$8.00
+47.1%
0%US$8.00US$8.00US$0.791
Apr ’22US$4.53
US$8.00
+76.6%
0%US$8.00US$8.00US$1.001
Mar ’22US$5.25
US$8.00
+52.4%
0%US$8.00US$8.00US$1.751
Feb ’22US$5.29
US$8.00
+51.2%
0%US$8.00US$8.00US$2.521
Jan ’22US$3.38
US$8.00
+136.7%
0%US$8.00US$8.00US$3.621
Dec ’21US$2.90
US$8.00
+175.9%
0%US$8.00US$8.00US$3.961

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies